{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:48:52Z","timestamp":1792162132432,"version":"4.4.0"},"reference-count":25,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2010,11,11]],"date-time":"2010-11-11T00:00:00Z","timestamp":1289433600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Objectives:\u2002<\/jats:bold>  <jats:sup>90<\/jats:sup>Y\u2010labeled anti\u2010CD66b monoclonal antibody clone BW 250\/183 was developed for treatment of tumors. The aim of the study was the analysis of CD66 expression in lymphoproliferative malignancies to expand the potential of anti\u2010CD66\u2010based therapy.<\/jats:p><jats:p><jats:bold>Patients and methods:\u2002<\/jats:bold> Bone marrow samples from 260 patients were examined for the expression of CD66 on tumor cells in 104 B\u2010chronic lymphocytic leukemias (B\u2010CLL), 28 mantle cell lymphomas (MCL), 22 follicular lymphomas (FCL), 15 marginal zone lymphomas (MZL), 12 lymphoplasmacytic lymphomas (LPL), 13 diffuse large B cell lymphomas (DLBCL), 4 T\u2010non\u2010Hodgkin lymphomas (T\u2010NHL), 3 B\u2010NHL not otherwise specified (B\u2010NHL NOS), 3 B acute lymphoblastic leukemias (B\u2010ALL), and in 56 multiple myelomas (MM) by flow cytometry.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> Positive (\u2265\u200320%) expression of CD66abce clone Kat4c was detected in 76% of B\u2010CLL and 76.8% of MM. The highest number of CD66abce\u2010positive samples was in MCL and LPL (96.4% of 28 and 91.7% of 12 patients, respectively). Expression of CD66b clone BW 250\/183 was examined in 114 of 260 samples. Positive expression was detected in 23.3% of B\u2010CLL (6\/35), 17.1% of MM (7\/30), and 21.4% of MCL (3\/14) samples.<\/jats:p><jats:p><jats:bold>Conclusion:\u2002<\/jats:bold> The expression of CD66b compared to CD66abce was lower in all measured samples. Use of radiolabeled anti\u2010CD66b antibody for the treatment of lymphoproliferative diseases appears to have limited preclinical substantiation.<\/jats:p>","DOI":"10.1111\/j.1600-0609.2010.01529.x","type":"journal-article","created":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T02:36:46Z","timestamp":1285900606000},"page":"496-501","source":"Crossref","is-referenced-by-count":11,"title":["Expression of CD66 in non\u2010Hodgkin lymphomas and multiple myeloma"],"prefix":"10.1111","volume":"85","author":[{"given":"Karban","family":"Josef","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mocikova","family":"Heidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pytlik","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klener","family":"Pavel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trneny","family":"Marek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,11,11]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceb.2006.08.008"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1326.004"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcb.2005.08.002"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.3747\/co.2007.109"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002779900146"},{"key":"e_1_2_6_7_2","first-page":"919","volume-title":"Leucocyte Typing V. White Cell Differentiation Antigens","author":"Hanenberg H","year":"1995"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-008-0044-0"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-007-0388-1"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.10020"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705182"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-008-0043-1"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0b013e3282f3de84"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.2174\/138920106778521578"},{"key":"e_1_2_6_15_2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3413\/nukmed-0200","article-title":"Myeloablative radioimmunotherapy with 188Re\u2010CD66mAb before stem cell transplantation. No increase of proinflammatory cytokine levels of TNF\u03b1","volume":"48","author":"Mutschler J","year":"2009","journal-title":"Nuklearmedizin"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19960315)65:6<740::AID-IJC5>3.0.CO;2-Z"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.9.6085"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2008.02867.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1165\/ajrcmb.11.2.8049082"},{"key":"e_1_2_6_20_2","first-page":"249","article-title":"Expression of CECAM\u20101 in pulmonary adenocarcinomas and their metastases","volume":"29","author":"Thom I","year":"2009","journal-title":"Anticancer Res"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19980330)76:1<148::AID-IJC23>3.0.CO;2-7"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.12.8454"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.3.565"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1080\/1042819021000033015"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05663.x"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002590100544"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2010.01529.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.2010.01529.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T08:38:37Z","timestamp":1698655117000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2010.01529.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,11]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["10.1111\/j.1600-0609.2010.01529.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2010.01529.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,11]]}}}